Receive our newsletter – data, insights and analysis delivered to you
  1. Uncategorised
March 31, 2021

Coronavirus company news summary – OraSure seeks FDA approval for Covid-19 rapid antigen test – BD gets FDA approval for combination Covid-19, flu rapid antigen test

By Chloe Kent

OraSure Technologies has submitted an application to the US Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of its Covid-19 rapid antigen test. The EUA would allow for the test to be used as an at-home prescription test, as well as for professional use in point-of-care (POC) settings. OraSure has started manufacturing the assay test alongside the EUA submission.

BD has received EUA from the FDA for its new, rapid antigen test that can detect SARS-CoV-2, influenza A and B in one sample. The BD Veritor System delivers results within 15 minutes and is expected to launch the test in the summer of 2021-2022.

Olive Labs and Concentric by Ginkgo are working together to provide a simple and accessible testing modality for Covid-19-pooled testing, targeting US schools operating hybrid or in-person learning. Concentric runs testing across 15 states, with more than 800 schools signed up for its affordable testing programme.

Related Companies

Content from our partners
Precision wire: The future of bespoke medical treatment
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
“This technique means everything to us”: How CGM devices empower users 
Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU